Navigation Links
ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
Date:8/19/2007

immuneregen.com" target="_new">http://www.immuneregen.com.

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre- clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-QSB for the three months ended March 31, 2007 and on Form 10-KSB for the twelve months ended December 31, 2006 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements. Available Topic Expert(s): For information on t
'/>"/>

SOURCE ImmuneRegen BioSciences

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
5. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
6. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
7. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
8. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
9. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Jan. 4, 2012   Unigene Laboratories, Inc. (OTCBB: ... manufacture and development of peptide-based therapeutics, announced that Ashleigh ... corporate overview at the Biotech Showcase™ 2012 in San ... a.m. PT (2:30 p.m. ET).  Mr. Palmer,s presentation will include ...
... Group, an international generic pharmaceuticals company, today announced ... Food & Drug Administration to market Methylphenidate Hydrochloride ... 40mg.  Actavis has first-to-file exclusivity on the 20mg, ... has commenced.  Methylphenidate Hydrochloride Extended-Release ...
Cached Medicine Technology:Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 2Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity 2
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... been shown to reduce seizures in patients with medication-resistant ... with an innovative electrode placement planning system developed by ... of seizures in nearly half of the implanted Rush ... good news for a large portion of the nearly ... seizures can,t be controlled with medications and who are ...
(Date:4/22/2014)... all lung cancers are small cell lung cancers ... to chemotherapy. However, researchers at Virginia Commonwealth University ... the mechanisms leading to this resistance that may ... primarily by mediating B-cell lymphoma 2 (Bcl-2) family ... Depending on their function, this family of proteins ...
(Date:4/22/2014)... Hopkins scientists have found a way to block abnormal ... of atherosclerosis, the main cause of heart attacks and ... The condition develops when fat builds inside blood vessels ... greatly reducing their ability to feed oxygen-rich blood to ... series of experiments, described April 7 in the journal ...
(Date:4/22/2014)... help rein in massive health care spending, a new ... find ways to incentivize pharmaceutical companies and device makers ... of examining existing medical technologies and their use, a ... what drugs and medical devices get created in the ... care spending with as little loss of health as ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... the woman, the less the idea bothered her , , ... comfortable with the idea of childlessness than men, new ... differences in how each gender views the pressures of ... women, parenting and parenthood mean different things," said study ...
... and advocates,to visit Capitol Hill Tuesday, ask Congress to ... WASHINGTON, Oct. 19 With political concerns,growing rapidly on ... of,private equity buyouts of nursing homes, a national caravan ... Monday where they will hold a,demonstration at the Pennsylvania ...
... drugs are unsafe for children under 6, advisers say., , , ... Food and Drug Administration advisory panel on Friday recommended a ... than 6. , Citing a number of studies that showed ... experts also recommended the drugs be tested on children to ...
... Oct. 19 With safety issues making,headlines, ... rugged,regulatory landscape. Organizations are relying on their ... affect production. Proper,staffing of quality roles is ... and a study by pharmaceutical benchmarking leader ...
... 19 The Department of,Labor,s Occupational Safety and ... health instruction that details OSHA policies and procedures,for ... may have,the potential for a dust explosion. ... our efforts on the,fire and explosion hazards that ...
... Ireland, Oct. 19 PulseLearning,(which was founded in 1999 ... on a second-hand computer set up in a child,s ... named fastest growing IT company in,Ireland at the ,2007 ... Awards, now in their eighth year, rank the 50 ...
Cached Medicine News:Health News:Childlessness Bothers Men More Than Women 2Health News:Childlessness Bothers Men More Than Women 3Health News:FDA Panel Recommends Ban on Cold Medicines for Kids 2Health News:FDA Panel Recommends Ban on Cold Medicines for Kids 3Health News:FDA Panel Recommends Ban on Cold Medicines for Kids 4Health News:Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance 2Health News:OSHA Issues New Combustible Dust Instruction 2Health News:PulseLearning (Founded in Child's Bedroom in an Irish Suburban Semi Eight Years Ago and Initially Run on a Second-Hand Computer) Today Named Fastest Growing IT Company in Ireland 2Health News:PulseLearning (Founded in Child's Bedroom in an Irish Suburban Semi Eight Years Ago and Initially Run on a Second-Hand Computer) Today Named Fastest Growing IT Company in Ireland 3Health News:PulseLearning (Founded in Child's Bedroom in an Irish Suburban Semi Eight Years Ago and Initially Run on a Second-Hand Computer) Today Named Fastest Growing IT Company in Ireland 4
... Special Protective Apron is made to ... a sterile gown. Uniquely it can ... field. Reaching through the back of ... released, and the protective apron will ...
... a 2 adjustable belt buckle. You adjust once ... Apron off your shoulders. And now theres our ... female anatomy. ,For additional back support try one ... pressure on the vertebrae and help "lift the ...
... is an extremely modular and flexible system that can ... patient is in the comfort of their home. The ... in a lightweight pouch. The alkaline batteries are in ... used is a standard flash memory card. EEG data ...
... Building on over 20 years ... handling platforms for the Life Sciences, ... more flexibility and possibilities for expansion ... the new easy-to-use software, Freedom EVOware, ...
Medicine Products: